



# An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis (BMS Protocol IM101240)

Status: Recruiting

## Eligibility Criteria

Age: Up to 18 years old

This study is NOT accepting healthy

Healthy Volunteers: volunteers

#### Inclusion Criteria:

- less than 18 years of age (unless currently or previously enrolled in an abatacept clinical trial and received abatacept) - diagnosis of Juvenile Idiopathic Arthritis (JIA) - currently receiving abatacept per treating physician's decision or received abatacept in a clinical trial

#### **Exclusion Criteria:**

- pregnant or breast feeding - history of cancer unless cancer free for at least 5 years - any serious acute or chronic medical condition other than JIA - history of frequently missing clinic appointments

### Conditions & Interventions

#### Conditions:

Arthritis & Rheumatic Diseases, Children's Health

Keywords:

Abatacept, Juvenile Idiopathic Arthritis

## More Information

**Description:** The objective of this study is to create an international registry with long-term follow-up to characterize and evaluate the safety of abatacept in juvenile idiopathic arthritis (JIA). The primary objective of the JIA registry is to describe the long-term safety of abatacept treatment for JIA by quantifying the incidence rates of serious infections, autoimmune disorders, and malignancies.

Contact(s): Bryce Binstadt - binstadt@umn.edu

Principal Investigator: Colleen Correll

IRB

**Number:** 1403M48721 **System ID:** 16752

Thank you for choosing StudyFinder. Please visit http://studyfinderstaging.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.